HEIDELBERG FACULTY OF MEDICINE

MOLECULAR VIROLOGY HEIDELBERG

HDV and the Interferon Response

Synergistic suppression of HDV persistence *in vitro* by co-treatment with investigational drugs targeting both extracellular and cell-division-mediated spreading pathways

Zhenfeng Zhang*[1], Tobias Walther[1], Florian A Lempp[1], Yi Ni[1,2] and Stephan Urban[1,2]

1 Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg;
2 German Center for Infection Research (DZIF) - Heidelberg Partner Site, Heidelberg;

Disclosures

consulting or speaking and/or research grants (last 5 years):

Gilead, Humabs, VirBio, Pepperprint, ENYO, Galapagos; MSD, Hepatera, MYR GmbH;

Patent holder and inventor on patents protecting Myrcludex B

HDV and the IFN-response

Gastroenterology 2018;154:1791–1804

HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon

Pascal Mutz,[1,2,3] Philippe Metz,[1] Florian A. Lempp,[1,4] Silke Bender,[1,2] Bingqian Qu,[1] Katrin Schöneweis,[1,4] Stefan Seitz,[1] Thomas Tu,[1] Agnese Restuccia,[1,2] Jamie Frankish,[5] Christopher Dächert,[5] Benjamin Schusser,[6] Ronald Koschny,[7] Georgios Polychronidis,[8] Peter Schemmer,[8,10] Katrin Hoffmann,[8] Thomas F. Baumert,[9] Marco Binder,[1,5] Stephan Urban,[1,4] and Ralf Bartenschlager[1,2,3,4]

[1]Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany; [2]Division of Virus-Associated Carcinogenesis (F170), German Cancer Research Center (DKFZ), Heidelberg, Germany; [3]HBIGS graduate school, Heidelberg, Germany; [4]German Centre for Infection Research (DZIF), partner site Heidelberg, Heidelberg, Germany; [5]Research Group "Dynamics of early viral infection and the innate antiviral response", Division Virus-associated carcinogenesis (F170), German Cancer Research Center (DKFZ), Heidelberg, Germany; [6]Reproductive Biotechnology, School of Life Sciences Weihenstephan, Technical University of Munich, Munich, Germany; [7]Department of Gastroenterology, Infection and Intoxication, University Hospital Heidelberg, Heidelberg, Germany; [8]Department of General-, Visceral- and Transplant Surgery, University Hospital Heidelberg, Heidelberg, Germany; and [9]Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Université de Strasbourg, Institut Hospitalo-Universitaire, Pôle Hépato-digestif, Nouvel Hôpital Civil, Strasbourg, France; [10]Division of Transplant Surgery, Medical University of Graz, Graz, Austria



Research Article
Viral Hepatitis

JOURNAL OF HEPATOLOGY

Hepatitis D virus replication is sensed by MDA5 and induces IFN-β/λ responses in hepatocytes

Graphical abstract



Highlights

- In contrast to HBV, HDV activates the IFN response in hepatocytes.
- MDA5 is the key pattern recognition receptor sensing HDV replication.
- HDV replication is insensitive to the MDA5-mediated self-induced IFN response.
- IFN treatment doesn't abolish intracellular HDV replication *in vitro*.

Authors

Zhenfeng Zhang, Christina Filzmayer, Yi Ni, ..., Florian W.R. Vondran, Ralf Bartenschlager, Stephan Urban

Correspondence

Stephan.Urban@med.uni-heidelberg.de (S.Urban)

Lay summary

In contrast to hepatitis B virus, infection with hepatitis D virus induces a strong IFN-β/λ response in innate immune competent cell lines. MDA5 is the key sensor for the recognition of hepatitis D virus replicative intermediates. An IFN-activated state did not prevent hepatitis D virus replication *in vitro*, indicating that hepatitis D virus is resistant to self-induced innate immune responses and therapeutic IFN treatment.



HBV is a stealth virus while HDV induced profound IFN-β/λ responses

HDV infection induces an IFN response in HepaRG cells

Time course of HDV infection and expression of IFN-induced MxA in the absence …..



Zhang, et al. J. Hepatology, 2018

……and in the presence of the entry inhibitor Myrcludex B



- HDV infection of HepaRG cells induces ISGs responses following HDV infection
- Myrcludex B/Bulevirtide inhibits de novo induced HDV IFN responses

MDA5 selectively senses HDV replication and let to induction of IFN-ß/λ





- **HDV infection activates IFN-β/λ responses in primary human hepatocytes**
- **Knock down of MDA5 abolishes IFN activation**



⇒ **MDA5 is the key sensor (PRR) for HDV replication**

Zhang, *et al*. J Hepatol. 2018.

IFN treatment of HDV infected hepatocytes marginally affects HDV replication



Zhang, et al. J. Hepatology, 2018



HDV replication is insensitive to IFNα and IFNλ treatment in resting hepatocytes

The effect of IFNs on dividing hepatocytes



Giersch *et al*., Gut, 2019.

Zhang *et al*. Int. HBV meeting. 2018. Taormina.

Cell-division-mediated HDV spread in innate immune defective and competent cells



Zhang et al. Int. HBV meeting. 2018. Taormina.

⇒ Cell-division-mediated HDV spread is suppressed in innate immune competent cell lines

Blocking the endogenous IFN response promotes HDV spread in HepaRG^{NTCP} cells



Ruxolitinib :
JAK1/2 inhibitor
blocks ISG induction



HDAg, Nuclei





HDAg, Nuclei



IFN treatment suppresses cell-division-mediated HDV spread in HuH7^{NTCP} cells

HuH7^{NTCP}
deficient in IFN induction
sensitive to IFN





⇒ Both, HDV-induced endogenous IFN responses **and** exogenous IFNα/λ treatment suppresses cell-division-mediated HDV spread

Establishment of in vitro model supporting extracellular spread of HDV

Stable integration of a 2.7 kb subgenomic HBV fragment and NTCP:
Provision of HBV envelope proteins and the receptor



HuH7^{NTCP}-HB2.7
(H7NB2.7)





Lempp, *et al*. Nature Communications. 2019.
Zhang, *et al*. Unpublished.

Use of H7NB2.7 cell culture model to investigate both HDV spreading pathways



Investigated Combinations

mono-treatment	co-treatment
MyrB	MyrB + IFN-α
Lonafarnib	MyrB + IFN-λ1
IFN-α	Lonafarnib + IFN-α
IFN-λ1	Lonafarnib + IFN-λ1
	MyrB + Lonafarnib
	IFN-α + IFN-λ1



Quantification of all HDAg positive cells

Evaluation of in vitro synergisms of drug using H7NB2.7 cells





- Lonafarnib promotes cell-division-mediated HDV spread probably by enhancing HDV replication.

Lempp, *et al*. Nature Communications. 2019

- IFN-α/-λ suppresses cell-division-mediated HDV spread

Zhang, et al. HBV Meeting. 2018. Taormina

⇒ **Drug combinations targeting both spreading pathways act synergistic**

Conclusion and clinical implications

Conclusions:

- HDV can spread by an extracellular route and by cell-division-mediated spread
- An *in vitro* infection model supporting both pathways has been established
- Co-treatment with drugs targeting the two different spreading pathways blocks HDV synergistically
- The system can be used to predict the strength of synergisms of drug combinations

Clinical implication for Myrcludex B

- The finding confirms the clinical observation of the Myr-203 study demonstrating a strong synergism of Myrcludex B/peg-IFN-α combination therapy



O-85, Wedemeyer et al.,: SAFETY AND EFFICACY OF 10mg (HIGH-DOSE) BULEVIRTIDE (MYRCLUDEX B) IN COMBINATION WITH PEG-INTERFERON ALPHA 2a OR TENOFOVIR IN PATIENTS WITH CHRONIC HBV/HDV CO-INFECTION: WEEK 24 INTERIM RESULTS OF THE MYR203 EXTENSION STUDY.

Acknowledgements



MOLECULAR VIROLOGY
HEIDELBERG

DZIF
German Centre for Infection Research

Group **Urban**: Yi Ni, Florian Lempp, Tobias Walther, Franziska Schlund, Lisa Walter, Anja Rippert, Thomas Tu, Bingqian Qu, Benno Zehnder, Shirin Nkongolo, Martina Weiss, Christa Kuhn, Katrin Schöneweis, Katrin Schöneweis, Volkan Sakin, Wenshi Wang. Eva Gnimah Gnouamozi, Talisa Richardt

Group **Bartenschlager**: Pascal Mutz, Nadine Gillich

Groups **Lohmann, Ruggieri and Binder**

Prof. **John Taylor**

Dr. **Camille Sureau**

DFG

Freiburg · Heidelberg · München
TRR179